Wir verwenden Cookies auf unserer Website. Einige von ihnen sind unerlässlich, während andere uns helfen, diese Website und Ihre Erfahrungen zu verbessern.

Notwendig Statistik Marketing
Auswahl bestätigen
Weitere Einstellungen

Hier finden Sie eine Übersicht aller verwendeten Cookies. Sie können ganzen Kategorien Ihre Zustimmung geben oder weitere Informationen anzeigen und bestimmte Cookies auswählen.

Alle auswählen
Auswahl bestätigen
Notwendig Cookies
Wesentliche Cookies ermöglichen grundlegende Funktionen und sind für die ordnungsgemäße Funktion der Website erforderlich.
Statistik Cookies
Statistik-Cookies sammeln anonym Informationen. Diese Informationen helfen uns zu verstehen, wie unsere Besucher unsere Website nutzen.
Marketing Cookies
Marketing-Cookies werden von Werbekunden oder Publishern von Drittanbietern verwendet, um personalisierte Anzeigen zu schalten. Sie tun dies, indem sie Besucher über Websites hinweg verfolgen

    Self-Emulsifying Drug Delivery Systems

    Facing the bioavailability challenge in drug delivery

    Sven Stegemann, Hassan Benameur, Thilo Schmierer, Martin Opitz

    Capsugel – A Division of Pfizer, Bornem (Belgium)

    Corresponding author: Dr. Sven Stegemann, Capsugel – A Division of Pfizer, Rijksweg 11, 2880 Bornem (Belgium), e-mail: sven.stegemann@pfizer.com

    SEDDS are pre-concentrates of excipients with a drug substance that form a thermodynamically stable micro-emulsion upon contact with aqueous media. The drug substance is kept in a solubilized form, thus improving the pharmacokinetic profile of BCS Class 2 drug substances and to optimize efficacy and safety [5].
    Self-microemulsion systems are developed by a rational development program taking into account the physicochemical and biopharmaceutical properties of the drug compound. Following careful selection of the right candidate, solubility screening is performed in single excipients and later on in a combination of different excipients. Phase diagrams are established for the excipient combinations in order to identify the right concentration of each component in conjunction with the drug substance. Through the use of innovative software programs (e. g. LipidexTM), the development time of SEDDS can be substantially reduced. The lead formulations are further characterized and tested in vitro before the final formulations are selected for the in vivo trials. The uniqueness of such formulation is the ability to solve not only the poor water solubility problem of API but to also enhance biopharmaceutical performance of the drug product formulation (bioavailability, food effect, transporters, and pre systemic metabolism).
    The selected lead formulation needs then be converted into a solid oral dosage form. As these SEDDS are either liquid or semi solid in nature. Their preparation generally starts with a simple blending process resulting in pre-concentrates which can be filled into two piece capsules on laboratory scale equipment (e. g. CFS 1200) for the initial in vivo testing. When larger or commercial quantities are required, the well characterized formulation is filled into two-piece capsules on the standard capsule filling machines online connected with a LEMS capsule sealing machine [24].

    Key words BCS Class 2 compound • Bioenhancement • Drug delivery • Lipid drug delivery systems • Self-emulsifying drug delivery systems

    © ECV- Editio Cantor Verlag (Germany) 2009


    pharmind 2009, Nr. 8, Seite 1409